- Home
- IPST vs HURA Comparison
IPST vs HURA Comparison
Compare IPST & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPST
- HURA
- Stock Information
- Founded
- IPST 2011
- HURA 2009
- Country
- IPST United States
- HURA United States
- Employees
- IPST N/A
- HURA N/A
- Industry
- IPST Beverages (Production/Distribution)
- HURA
- Sector
- IPST Consumer Staples
- HURA
- Exchange
- IPST Nasdaq
- HURA Nasdaq
- Market Cap
- IPST 163.4M
- HURA 131.8M
- IPO Year
- IPST 2024
- HURA N/A
- Fundamental
- Price
- IPST $0.63
- HURA $2.29
- Analyst Decision
- IPST
- HURA Strong Buy
- Analyst Count
- IPST 0
- HURA 2
- Target Price
- IPST N/A
- HURA $11.50
- AVG Volume (30 Days)
- IPST 445.4K
- HURA 173.0K
- Earning Date
- IPST 11-25-2025
- HURA 11-13-2025
- Dividend Yield
- IPST N/A
- HURA N/A
- EPS Growth
- IPST N/A
- HURA N/A
- EPS
- IPST N/A
- HURA N/A
- Revenue
- IPST $7,058,550.00
- HURA N/A
- Revenue This Year
- IPST N/A
- HURA N/A
- Revenue Next Year
- IPST N/A
- HURA N/A
- P/E Ratio
- IPST N/A
- HURA N/A
- Revenue Growth
- IPST N/A
- HURA N/A
- 52 Week Low
- IPST $0.27
- HURA $1.80
- 52 Week High
- IPST $4.00
- HURA $7.20
- Technical
- Relative Strength Index (RSI)
- IPST N/A
- HURA 39.99
- Support Level
- IPST N/A
- HURA $2.16
- Resistance Level
- IPST N/A
- HURA $2.61
- Average True Range (ATR)
- IPST 0.00
- HURA 0.13
- MACD
- IPST 0.00
- HURA -0.02
- Stochastic Oscillator
- IPST 0.00
- HURA 25.51
About IPST Heritage Distilling Holding Company Inc. Common Stock
Heritage Distilling Holding Co Inc is a craft distiller producing, marketing, and selling a diverse line of award-winning craft spirits, including whiskeys, vodkas, gins, rums, and ready-to-drink canned cocktails. The company sells its products through wholesale distribution, directly to consumers through its owned and operated distilleries and tasting rooms located in Washington and Oregon, and by shipping directly to consumers online, where legal. Currently, it sells products in the Pacific Northwest with limited distribution in other states throughout the U.S.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.